Abstract Library

#3035 Large-Cell Neuroendocrine Carcinoma of the Lung in Elderly Patient: Case Report and Review of Literature

Introduction: Lung neuroendocrine tumors account for less than 25% of lung cancers.Which is a rare malignant tumor with an aggressive profile has often already affected lymph nodes at presentation and it is de novo metastatic in nearly 40% of cases.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Aliane H, Ghomari S,

Keywords: Large cell neuroendocrine carcinoma, Biopsy, Immunohistochemical staining, Chemosensitivity, Prognosis,

#2929 Type III Gastric Neuroendocrine Neoplasms: Is Local Excision Sufficient in Selected Cases?

Introduction: As per ENETS Guidelines, patients with type III gastric neuroendocrine neoplasms (t-III g-NEN), need to undergo partial or total gastrectomy. Data for less-extensive resections are limited.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Exarchou K

Authors: Exarchou K, Kameniarz L, Tsoli M, Victor A, Oleinikov K,

Keywords: T-III gNEN, EMR, ESD, wedge resection,

#2887 CHOI Criteria Are More Accurate Than RECIST in Advanced Pancreatic Neuroendocrine Tumors Treated with Sunitinib: Data from the CRIPNET-GETNE1504 Study

Introduction: Comparative data suggest greater accuracy of Choi vs RECIST in some cancers such as pancreatic neuroendocrine tumors (panNET) treated with antiangiogenic agents.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Jimenez-Fonseca P, Fernandez del Valle A, Solis M, Garcia Carbonero R, Custodio A,

Keywords: CHOI, RECIST, Response, Sunitinib, Survival,

#2876 Efficacy of Surufatinib in Western Patients (pts) with Pancreatic Neuroendocrine Tumors (PanNETs)

Introduction: Surufatinib is a targeted inhibitor of tyrosine kinases VEGFR1, 2, & 3, FGFR1, and CSF-1R. The safety profile was favorable in 2 completed studies (NCT02133157, NCT02267967) conducted in China. A recent phase 3 placebo controlled study (NCT02588170) confirmed safety, and demonstrated superior efficacy (PFS: 9.2 v 3.8 months) of Surufatinib in Chinese pts with advanced extra-pancreatic NETs (epNET).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Dasari A, Paulson S, Sung M, Tucci C, Kauh J,

Keywords: Neuroendocrine Tumors, Pancreatic, Surufatinib,

#2871 Increase of Ki-67 Index over Time and Influence on All-Cause Mortality in Patients with Neuroendocrine Neoplasms (NEN)

Introduction: Increase of Ki-67 index in NEN over time in relation to progression and a potential influence on prognosis is scarcely studied.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Holmager P

Authors: Holmager P, Langer S, Federspiel B, Willemoe G, Garbyal R,

Keywords: Ki-67 index, Prognosis, Mortality,